SILVER SPRING, MD. – A Food and Drug Administration advisory panel, citing numerous problems with cangrelor’s clinical trial program, has recommended against approval of the short-acting intravenous...

Field of Interest: Cardiology

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.